Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaLisa Zimmer, Dirk Schadendorf, Alexander Enk et al.|PLoS ONE|2015Cited by 292
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Selma Ugurel et al.|The Lancet|2023Cited by 75
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter J. Mohr et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 19
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter Mohr et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 14